Drugs for exceptionally rare diseases: a commentary on Hughes et al

Research output: Working paperDiscussion paper

Standard

Drugs for exceptionally rare diseases: a commentary on Hughes et al. / Claxton, K.; McCabe, C.; Tsuchiya, A.; Raftery, J.

QJM, 2006.

Research output: Working paperDiscussion paper

Harvard

Claxton, K, McCabe, C, Tsuchiya, A & Raftery, J 2006 'Drugs for exceptionally rare diseases: a commentary on Hughes et al' QJM.

APA

Claxton, K., McCabe, C., Tsuchiya, A., & Raftery, J. (2006). Drugs for exceptionally rare diseases: a commentary on Hughes et al. QJM.

Vancouver

Claxton K, McCabe C, Tsuchiya A, Raftery J. Drugs for exceptionally rare diseases: a commentary on Hughes et al. QJM. 2006.

Author

Claxton, K. ; McCabe, C. ; Tsuchiya, A. ; Raftery, J. / Drugs for exceptionally rare diseases: a commentary on Hughes et al. QJM, 2006.

Bibtex - Download

@techreport{faf0185ca151467cbada60bdd70eebce,
title = "Drugs for exceptionally rare diseases: a commentary on Hughes et al",
abstract = "Recently in this journal, Hughes and colleagues discussed special funding status to ultra-orphan drugs. They concluded that there should be a uniform policy for the provision of orphan drugs across Europe; that complete restriction was impractical, and that UK policy should aspire to the values of the EU directive on orphan drugs. We critically assess these arguments, demonstrating that they failed to justify special status for treatments for rare diseases.",
author = "K. Claxton and C. McCabe and A. Tsuchiya and J. Raftery",
year = "2006",
language = "English",
publisher = "QJM",
type = "WorkingPaper",
institution = "QJM",

}

RIS (suitable for import to EndNote) - Download

TY - UNPB

T1 - Drugs for exceptionally rare diseases: a commentary on Hughes et al

AU - Claxton, K.

AU - McCabe, C.

AU - Tsuchiya, A.

AU - Raftery, J.

PY - 2006

Y1 - 2006

N2 - Recently in this journal, Hughes and colleagues discussed special funding status to ultra-orphan drugs. They concluded that there should be a uniform policy for the provision of orphan drugs across Europe; that complete restriction was impractical, and that UK policy should aspire to the values of the EU directive on orphan drugs. We critically assess these arguments, demonstrating that they failed to justify special status for treatments for rare diseases.

AB - Recently in this journal, Hughes and colleagues discussed special funding status to ultra-orphan drugs. They concluded that there should be a uniform policy for the provision of orphan drugs across Europe; that complete restriction was impractical, and that UK policy should aspire to the values of the EU directive on orphan drugs. We critically assess these arguments, demonstrating that they failed to justify special status for treatments for rare diseases.

M3 - Discussion paper

BT - Drugs for exceptionally rare diseases: a commentary on Hughes et al

PB - QJM

ER -